Parallel inhibition of active force and relaxed fiber stiffness by caldesmon fragments at physiological ionic strength and temperature conditions: additional evidence that weak cross-bridge binding to actin is an essential intermediate for force generation.
Previously we showed that stiffness of relaxed fibers and active force generated in single skinned fibers of rabbit psoas muscle are inhibited in parallel by actin-binding fragments of caldesmon, an actin-associated protein of smooth muscle, under conditions in which a large fraction of cross-bridges is weakly attached to actin (ionic strength of 50 mM and temperature of 5 degrees C). These results suggested that weak cross-bridge attachment to actin is essential for force generation. The present study provides evidence that this is also true for physiological ionic strength (170 mM) at temperatures up to 30 degrees C, suggesting that weak cross-bridge binding to actin is generally required for force generation. In addition, we show that the inhibition of active force is not a result of changes in cross-bridge cycling kinetics but apparently results from selective inhibition of weak cross-bridge binding to actin. Together with our previous biochemical, mechanical, and structural studies, these findings support the proposal that weak cross-bridge attachment to actin is an essential intermediate on the path to force generation and are consistent with the concept that isometric force mainly results from an increase in strain of the attached cross-bridge as a result of a structural change associated with the transition from a weakly bound to a strongly bound actomyosin complex. This mechanism is different from the processes responsible for quick tension recovery that were proposed by Huxley and Simmons (Proposed mechanism of force generation in striated muscle. Nature. 233:533-538.) to represent the elementary mechanism of force generation.
Kraft
T
T
Department of General Physiology, University of Ulm, Germany.
Chalovich
J M
JM
Yu
L C
LC
Brenner
B
B
D000199:Actins / Q000378:metabolism; D000818:Animals; D002148:Calmodulin-Binding Proteins / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology*; D002918:Chymotrypsin; D005895:Gizzard, Avian; D066298:In Vitro Techniques; D007700:Kinetics; D008433:Mathematics; D018613:Microscopy, Confocal; D008954:Models, Biological; D009119:Muscle Contraction / Q000187:drug effects*; D018485:Muscle Fibers, Skeletal / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D018482:Muscle, Skeletal / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D009130:Muscle, Smooth; D010446:Peptide Fragments / Q000378:metabolism / Q000494:pharmacology*; D011485:Protein Binding; D011817:Rabbits; D014422:Turkeys
D000199:Actins; D002148:Calmodulin-Binding Proteins; D010446:Peptide Fragments; D002918:Chymotrypsin